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We previously identified apoptosis stimulating protein of p53 (Aspp1) as an endothelial-specific gene functioning in mouse embryogenesis. To
investigate the in vivo role of Aspp1, we generated Aspp1 knockout mice by targeted disruption. Aspp1−/− embryos showed subcutaneous edema
and disorganized lymphatic vasculature. Morphological changes in lymphatic endothelial cells and isolated lymphatic islands were detected in
Aspp1−/− embryos. Lymphangiography by injecting dye subcutaneously into the embryonic forelimb showed defective lymphatic drainage
function and obstruction in collecting lymphatic vessels of Aspp1−/− embryos. Interestingly, Aspp1−/− adult mice resolved these lymphatic
functional defects seen during embryogenesis, but lymphangiography in Aspp1−/− adult mice revealed abnormal patterns in collecting lymphatic
vessels. Since Aspp proteins reportedly enhance apoptotic activity of p53, we asked whether p53 deficiency also affected lymphatic vessel
development. Analysis of p53 knockout or Aspp1; p53 double knockout mice showed that p53 loss did not affect lymphatic vessels. These results
indicate that Aspp1 plays a crucial role in the initial assembly and function of lymphatic vessels during mouse development in a p53-independent
manner. Here we report novel lymphatic vascular phenotypes in Aspp1−/− mice; subcutaneous edema detected only during embryogenesis,
delayed lymphatic vessel formation, and mispatterned collecting lymphatic vessels.
© 2008 Elsevier Inc. All rights reserved.Keywords: Development; Embryonic edema; Endothelial; Lymphatic vessels; MouseIntroduction
The vertebrate circulatory system is composed of closely
related blood and lymphatic vessels. The lymphatic system plays
a role in maintaining tissue fluid homeostasis by transporting
tissue fluid and extravasated plasma proteins back into the blood
vessel circulation. Lymphatic capillaries are a highly permeable
vascular network of thin-walled endothelial cells which drain
protein-rich lymph from extracellular spaces withinmost organs.
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doi:10.1016/j.ydbio.2008.01.023lymphatic vessels, which contain a muscular and adventitial
layer (Oliver and Alitalo, 2005). Dysfunction or impaired dev-
elopment of lymphatic vessels causes lymphedema. The lym-
phatic system also contributes to absorption of lipids from the
intestinal tract and to the immune response by transporting
foreign molecules, leukocytes and antigen-presenting cells to
lymphoid organs such as the lymph nodes, spleen, thymus,
tonsils, and Peyer's patches.
The availability of specific markers and growth factors for
lymphatic vessels has enabled the investigation of molecular
and cellular mechanisms of their development in physiological
and pathological conditions (Hong et al., 2004). Specification of
lymphatic endothelial cell fate has been established by the
homeobox gene Prox1 at the initial stage of lymphatic dev-
elopment (Wigle and Oliver, 1999; Wigle et al., 2002). Lym
phatic endothelial cell development also depends on vascular
endothelial growth factor receptor 3 (VEGFR3)/neuropilin-2
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initially-formed lymphatic capillary plexus is subsequently re-
modeled into a hierarchical vessel network of collecting lym-
phatic vessels and capillaries. Analysis of mice carrying mutant
ephrinB2 with deletion of the PDZ interaction site has revealed
defects in lymphatic remodeling and luminal valve formation of
collecting lymphatic vessels (Makinen et al., 2005). Agenesis of
lymphatic valves, abnormal lymphatic vessel patterning, and
increased pericyte investment in lymphatic vessels are detected
in Foxc2-null mice (Petrova et al., 2004). On the other hand,
smooth muscle cell coverage is impaired by loss of Angio-
poietin-2 (Gale et al., 2002).
We previously identified Aspp1 as an endothelial-specific
gene in mice by gene-trap expression screening (Hirashima et
al., 2004). The ASPP family is evolutionarily conserved from
nematodes to vertebrates and in humans and mice includes three
members, ASPP1, ASPP2 and the inhibitory ASPP (iASPP)
(Trigiante and Lu, 2006). ASPP stands for ankyrin-repeat-,
SH3-domain- and proline-rich-region-containing proteins based
on characteristic structural motifs, and also for apoptosis-
stimulating protein of p53 and its family members p63 and p73,
based on ASPP1 and ASPP2 function (Bergamaschi et al.,
2004; Samuels-Lev et al., 2001). ASPP proteins enhance both
DNA-binding and transactivation function of p53 family
proteins on promoters of Bax, PIG3, and PUMA promoters to
stimulate apoptosis. ASPP2/53BP2 was also previously identi-
fied as an interacting partner of several proteins (Trigiante and
Lu, 2006). Vives et al. (2006) recently reported that Aspp2−/−
mice show defects in brain and heart development leading to
postnatal lethality, which is significantly enhanced in a p53+/−
background. Aspp2+/− mice develop spontaneous tumors whose
onset is accelerated either by γ-irradiation or in a p53+/−
background. Aspp2 is thus a haploinsufficient tumor suppressor
that shares overlapping function with p53 in mouse develop-
ment and tumor suppression. On the other hand, in vivo role of
Aspp1 has not been addressed to date.
In this study, we generated and characterized Aspp1-deficient
mice. Aspp1−/− embryos showed subcutaneous edema related to
defects in lymphatic vessel development and drainage function.
However, Aspp1−/− adult mice did not show overt abnormalities
or signs of lymphedema, and lymphatic drainage occurred.
Although Aspp1 has been shown to serve as a positive mo-
dulator of p53 activity, we asked whether Aspp1 functions with
p53 but did not detect evidence of p53 involvement in lym-
phatic vessel development. Here we present the roles for an
endothelial-specific p53-binding protein, Aspp1, in lymphatic
vessel development and function during mouse development.
Materials and methods
Generation of Aspp1+/− mice
We used a mouse Aspp1 genomic clone from a 129S6/SvEvTac BAC library
(RPCI-22) to construct the Aspp1 targeting vector. Part of the second exon and
whole third exon (between EcoRI and EcoRV sites in Fig. 1A) were replaced
with an IRES–lacZ and loxP–PGK-neo–loxP cassette. For gene targeting,
4.9 kb of 5′ and 3.6 kb of 3′ homology regions were used. The vector was
linearized with NotI and electroporated into R1 ES cells, and colonies wereselected in 150 μg/ml of G418 (Nagy et al., 1993). Correctly targeted ES clones
were identified by Southern blot analysis using the 5′-flanking, 3′-flanking, and
neo-probes. Chimeric mice were generated by morula aggregation (Nagy et al.,
1993), and males were crossed with ICR (Harland Sprague Dawley) random
outbred females. After successful germline transmission of the targeted allele,
the floxed PGK-neo cassette was removed by crossing with a Cre deleter strain
(a gift from A. Nagy, Samuel Lunenfeld Research Institute, Toronto, Canada).
Deletion was verified by Southern blotting using the three probes mentioned
above (Fig. 1B, data not shown). We designate heterozygous mice carrying the
targeted locus without neo as Aspp1+/−. Genotyping of Aspp1+/− mice was also
performed by PCR analysis of tail DNA or yolk sac at an annealing temperature
of 65 °C with the following primers: Aspp1-S, 5′-TCTGGCTTCCTGTCAG-
GACATC-3′; Aspp1-A, 5′-TAGCACATTTGCTGCTCTTGTC-3′; and pA-S,
5′-ATATCTGGGAAGTCCCTTCCAC-3′. The wild-type allele gave a 239-bp
band, whereas the mutant allele gave a 336-bp band.
Mice
A colony of p53+/− (Zhang et al., 2004) mice were maintained as described.
Noon on the day of detection of the vaginal plug was detected was considered
E0.5. Embryos were genotyped by PCR analysis of tail DNA. For BrdU
incorporation assay, embryos were dissected 2.5 h after intraperitoneal injection
of BrdU (3 mg) into pregnant females. Animal experiments were approved by
the Animal Research Committee of Keio University School of Medicine and
carried out in accordance with the animal experimentation guidelines of the Keio
University School of Medicine.
RT-PCR
Individual yolk sacs and embryos at E8.5 from Aspp1+/− intercrosses were
dissected and used to isolate total RNA using Trizol (Invitrogen), according to
the manufacturer's instructions. Three micrograms of total RNA was reverse-
transcribed using the SuperScript first-strand synthesis system for RT-PCR
(Invitrogen). First-strand cDNA was used for PCR with specific primers for
Aspp1 (forward, 5′-CGCAAAGATGAAAACGAGAC-3′; reverse, 5′-CACC-
TTGCTCTTGTTCAAGG-3′) and, as a control, Hprt (forward, 5′-GCTGG-
TGAAAAGGACCTCT-3′; reverse, 5′-CACAGGACTAGAACACCTGC-3′).
Quantitative real-time PCR analysis was performed in PECAM-1+ LYVE-1+
CD45− cells purified from the skin at E14.5. Total RNA was isolated from
sorted cells with an RNeasy Mini Kit and RNase-Free DNase Set (Qiagen),
according to the manufacturer's instructions. First-strand cDNA was syn-
thesized as described, and used for analysis with TaqMan Gene Expression
Assays (Applied Biosystems) for Gapdh (Mm99999915_g1) and Prox1
(Mm00435969_m1).
Western blot analysis
Anti-Aspp1 antibody was generated in rabbits against a peptide correspond-
ing to amino acid 477–490 (accession number Q62415 in protein sequence
database of NCBI) encoded by a part of Aspp1 exon 11. Lysates were prepared
from brain of adult mice, and western blot analysis was performed with an anti-
Aspp1 antibody.
Immunohistochemistry
We used rat anti-LYVE-1 (clone ALY7, Morisada et al., 2005), Armenian
hamster anti-PECAM-1 (clone 2H8, Endogen), rabbit anti-β-galactosidase
(Invitrogen), rat anti-PECAM-1 (clone Mec13.3, BD Pharmingen), Cy3-
conjugated mouse anti-α-smooth muscle actin (clone 1A4, Sigma), rabbit
anti-Prox1 (Covance), rabbit anti-Ki67 (Abcam), Syrian hamster anti-podopla-
nin (clone 8.1.1, Developmental Studies Hybridoma Bank), and rat anti-VE-
cadherin (clone 11D4.1, BD Pharmingen) antibodies. For immunofluorescence,
we used Alexa Fluor 488-, Alexa Fluor 546-, Cy3-, or Cy5-conjugated
secondary antibodies (Invitrogen and Jackson ImmunoResearch). For LYVE-1
staining with 3,3′-diaminobenzidine (DAB, Dojindo) as a substrate, we used
horseradish peroxidase-conjugated anti-rat IgG antibody (Biosource). BrdU
incorporation assay was performed with BrdU Cell Proliferation Assay
Fig. 1. Targeted disruption of the Aspp1 gene. (A) Schematic representation of the gene targeting strategy. A portion of the second exon and the entire third exon were
deleted at the Aspp1 locus, and an IRES–lacZ sequence was inserted to indicate Aspp1 expression. The floxed PGK-neo cassette in the targeted locus was removed by
Cre-mediated recombination. Heterozygous mice carrying the targeted locus without neo are designated Aspp1+/−mice here. Exons are shown as filled boxes with the
exon number. Probes used for Southern blot analysis are shown as hatched boxes (5′-, 3′-flanking, and neo probes). Primers for PCR genotyping are shown as
arrowheads (Aspp1-S, Aspp1-A, and pA-S). B, BamHI; H, HincII; RI, EcoRI; RV, EcoRV; S, SacI. (B) Southern blot analysis. Results with 5′- and 3′-flanking probes
are shown in left and right panels, respectively. (C) PCR genotyping with Aspp1-S, Aspp1-A, and pA-S primers. (D) RT-PCR analysis for Aspp1. Hprt is detected as a
control. (E) Western blot analysis of Aspp1.
151M. Hirashima et al. / Developmental Biology 316 (2008) 149–159(Calbiochem) and Alexa Fluor 546-conjugated mouse anti-BrdU (clone PRB-1,
Invitrogen), according to the manufacturer's instructions.
For immunohistochemical analysis of embryonic back skin, whole embryos
were dissected between E14.5 and E15.5 and fixed in 4% paraformaldehyde
(PFA)/PBS at 4 °C for 15–20 min. The back skin was peeled off and further
fixed in 4% PFA/PBS at 4 °C overnight. Tissues were washed in PBS with 0.2%
Triton X-100 (PBT) at 4 °C for 30 min twice, blocked in PBT containing 1%
bovine serum albumin at room temperature for 1 h, and stained with primary
antibodies in blocking solution at 4 °C overnight. Tissues were washed in PBT
for 30 min 3 times at 4 °C and twice at room temperature, followed by staining
with secondary antibodies in blocking solution at 4 °C overnight. Tissues were
washed in PBT for 30 min 3 times at 4 °C and twice at room temperature. Back
skin was flat-mounted on slide glasses in ProLong Antifade (Invitrogen).
Confocal microscopy was carried out on an Olympus FV-1000 (Olympus).
To investigate differentiation into lymphatic endothelial cells, E11.5
embryos were fixed in 4% PFA/PBS at 4 °C overnight, mounted in 1.5%agarose gel and cut into 500 μm transverse sections with a microslicer (D.S.K,
DTK-1000). Whole-mount sliced tissues were stained for Prox1 and analyzed by
confocal microscopy.
For LYVE-1 staining, gut and heart were dissected from E17.5 embryos and
fixed in methanol/dimethyl sulfoxide (4:1) at 4 °C overnight. Endogenous
peroxidase activity was quenched with 0.3% hydrogen peroxide in methanol at
room temperature for 1 h, followed by rehydration in PBT. Antibody staining
was performed as described above. Immunoreactivity was visualized with
0.025% DAB and 0.08% NiCl2 in PBT. The number of isolated LYVE-1
+
lymphatic islands was measured on the entire surface of stained heart.
For immunohistochemical analysis on sections, dissected embryos were
processed according to the AMeX methods (Sato et al., 1986). Embryos were
embedded in paraffin and cut into 4 μm sections. After removing paraffin,
sections were washed in PBS, blocked in PBS containing 1% bovine serum
albumin at room temperature for 1 h, and stained with primary antibodies in
blocking solution at 4 °C overnight. Sections were washed in PBS for 10 min 3
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temperature for 2 h, and washed in PBS for 10 min 3 times at 4 °C. Specimens
were mounted in ProLong Antifade and analyzed by confocal microscopy.
Profiles of PECAM-1+/LYVE-1+ lymphatic vessels and PECAM-1+/LYVE-1−
blood vessels were measured with ImageJ 1.37.
Lymphangiography
To visualize functional lymphatic vessels, FITC-dextran (Sigma, MW=
2000 kDa, 8 mg/ml in PBS) or Evans blue dye (Sigma, 10 mg/ml in PBS) was
injected subcutaneously into the back of the embryonic forelimb or into the
footpad of the hindlimb of adult mice. Lymphatic flow carrying FITC-dextran in
embryos was analyzed by fluorescence microscopy.
Flowcytometry
E11.5 embryos were dissected and tissues except for the neural tube and
internal organs were analyzed. E14.5 embryos were dissected and the skin was
peeled for cell sorting. Tissues were minced and treated with PBS containing
0.05% collagenase S-1 (Nitta gelatin), 1.2 U/ml dispase (Gibco), and 50 μg/ml
DNaseI (Roche) at 37 °C for 30 min to create single cell suspensions. Non-
specific binding to Fc receptors was blocked in PBS/5% FCS with anti-CD16/
CD32 (clone 2.4G2; BD Pharmingen) for 10 min on ice. Cells were stained withFig. 2. Aspp1 is expressed in blood vessel and lymphatic endothelial cells at E14.5. (A
was performed with antibodies to PECAM-1 (red), LYVE-1 (blue), and to β-galact
venous and lymphatic (arrows) endothelial cells. LacZ reporter expression is also de
fluorescence confocal microscopy of embryonic sections was performed with antib
typical lymphatic vessel surrounding an artery. (D) X-gal staining of Aspp1-lacZ
counterstaining with nuclear fast red. This particular section shows a typical lymph
Aspp1-lacZ is expressed in blood vessel endothelial cells, lymphatic endothelial cells
lymph sac. Scale bars, 50 μm.phycoerythrin (PE)-conjugated anti-CD45 (BD Pharmingen) and biotinylated
anti-LYVE-1 for 20 min on ice, followed by washing twice in PBS/5% FCS. To
sort lymphatic endothelial cells, CD45+ cells were depleted by AutoMACS
following incubation with anti-PE beads for 20 min on ice. Cells were stained
with Fluorescein isothiocyanate-conjugated anti-PECAM-1 (BD Pharmingen)
and allophycocyanin-conjugated straptavidin (BD Pharmingen) for 20 min on
ice, followed by washing 3 times in PBS/5% FCS. Cells were further stained in
PBS/5%FCS with 1 μg/ml propidium iodide (Molecular Probes) to exclude
dying cells from analysis. Analysis and cell sorting of PECAM-1+/LYVE-1+/
CD45− lymphatic endothelial cells were performed with FACS Calibur and
FACS Vantage (both, Becton Dickinson), respectively.Results
Generation of Aspp1−/− mice
To investigate Aspp1 function, we inactivated the Aspp1
gene by targeted disruption in embryonic stem (ES) cells. The
targeting vector was designed to replace a portion of second
exon and whole third exon of the Aspp1 gene with an internal
ribosomal entry site (IRES) and β-galactosidase (lacZ) reporter, B) Triple fluorescence confocal microscopy of Aspp1-lacZ embryonic sections
osidase, a reporter of Aspp1 expression (green). Aspp1 is expressed in arterial,
tected in blood cells (asterisk) and mesenchymal cells (arrowheads). (C) Double
odies to PECAM-1 (red) and LYVE-1 (green). This particular section shows a
embryonic sections was performed with standard procedures and followed by
atic vessel surrounding an artery, and dashed rectangle area is shown in inset.
(arrows), some blood cells (asterisk), and mesenchymal cells. a, artery; v, vein; ls,
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vector, selected with G418, and screened for correct gene-
targeting by Southern blot analysis with the 5′-, 3′-flanking, and
neo probes (Fig. 1B, data not shown). Heterozygous ES cells
were used for generation of chimeric mice which were crossed
with wild-type ICR females for germline transmission. The
floxed PGK-neo cassette in the originally targeted locus was
removed by Cre-mediated recombination to generate the tar-
geted locus without neo. This removal of the PGK-neo cassette
was also confirmed by Southern blot analysis with the 5′-, 3′-
flanking, and neo probes and by PCR of tail DNA (Figs. 1B, C;
data not shown). Heterozygous mice carrying the targeted locus
without neo are designated Aspp1+/− mice in this study. To
verify loss of Aspp1 gene products in Aspp1−/− mice, RT-PCR
(Fig. 1D) and western blot (Fig. 1E) analysis were performed.
Both assays confirmed the absence of Aspp1 transcripts and
protein in Aspp1−/− mice. Of 646 postnatal offspring from
Aspp1+/− intercrosses, we found that homozygous mutant mice
for the Aspp1 gene were viable and that mice were born at a
nearly normal Mendelian frequency (Aspp1+/+ 24.8%, Aspp1+/−
54.0%, and Aspp1−/− 21.2%). Aspp1−/− pups weighed less
than controls at 2 weeks of age (Aspp1+/+, 7.0±0.6 g, n=15;
Aspp1+/−, 6.6±1.1 g, n=29, p=not significant; Aspp1−/−, 5.3±
1.1 g, n=22, pb0.0001) but eventually caught up with littermate
control mice. Mutant mice lived for more than 1 year without
overt abnormality, and were fertile (data not shown).Fig. 3. Aspp1−/− embryos show subcutaneous edema and distension of lymphatic ve
subcutaneous edema (arrowheads) in Aspp1−/− embryos. (C, D) H&E staining of sec
vessels (arrows) in the skin of Aspp1−/− embryos than in littermate controls. The heart
Double fluorescence confocal microscopy was performed with an antibody to LYVE-
(red) on adjacent sections at E14.5. PECAM-1 marks all endothelial cells, whereas
(arrows) and arteries (arrowheads), respectively. Distended lymphatic vessels are de
unaffected. Scale bars, 100 μm. (I–K) Vessel profiles of lymphatic vessels (LV) and
n=4; *, pb0.05; **, pb0.01; N.S.=not significant.Aspp1−/− embryos showed subcutaneous edema and distension
of lymphatic vessels at mid-gestation
Since Aspp1−/− pups were initially slightly growth-retarded,
we investigated embryonic phenotypes. Of 899 embryos from
Aspp1+/− intercrosses examined between embryonic day (E) 8.5
and E18.5, the expected ratio of genotypes was observed
(Aspp1+/+ 25.0%, Aspp1+/− 49.2%, and Aspp1−/− 25.8%). X-
gal staining of Aspp1-lacZ embryos showed that β-galactosidase
activity was specifically detected in endothelial cells at E9.5 (data
not shown), consistent with our previous analysis of Aspp1 gene-
trapped mice (Hirashima et al., 2004). We then asked whether
Aspp1 is expressed in lymphatic endothelial cells. Lymphatic
endothelial cells can be detected as PECAM-1+/LYVE-1+ cells at
E14.5, although PECAM-1 staining in lymphatic endothelial
cells is weaker than that in blood vessels (Morisada et al., 2005).
Triple fluorescence confocal microscopy of Aspp1-lacZ embryos
with antibodies to PECAM-1, LYVE-1, and β-galactosidase
showed that Aspp1 is expressed in lymphatic endothelial cells
and blood vessel endothelial cells (Figs. 2A, B). LacZ reporter
expression is also detected in blood cells and mesenchymal cells
(Figs. 2A, B; asterisk and arrowheads, respectively). To confirm
the lacZ reporter expression at greater sensitivity, we detected X-
gal-stained cells in Aspp1-lacZ embryonic sections. Double
fluorescence confocal microscopy with antibodies to PECAM-1
and LYVE-1 showed a typical lymphatic vessel surrounding anssels at E14.5. (A, B) Lateral and frontal views of whole-mount embryos show
tions detects a thicker dermal layer (arrowheads) and more distended lymphatic
(h) is morphologically normal in Aspp1−/− embryos. Scale bars, 500 μm. (E–H)
1 (green) or α-smooth muscle actin (green) combined with PECAM-1 antibodies
localization of LYVE-1 and α-smooth muscle actin indicates lymphatic vessels
tected in the skin of Aspp1−/− embryos, whereas blood vessels appear relatively
blood vessels (BV) in embryonic sections at E14.5. Aspp1+/+, n=3; Aspp1−/−,
154 M. Hirashima et al. / Developmental Biology 316 (2008) 149–159artery (Fig. 2C). Analysis of cross sections of Aspp1-lacZ
embryos confirmed that lacZ reporter is detected in blood vessel
endothelial cells, lymphatic endothelial cells, some blood cells,
and mesenchymal cells (Fig. 2D).Fig. 4. Aspp1−/− embryos show disorganized lymphatic vessels. (A–L) Whole-mount
with antibodies to PECAM-1 (red) and LYVE-1 (green) at E14.5 (A–F) and E15.5 (G–
unaffected in Aspp1−/− embryos. (C, D) At E14.5, LYVE-1 staining shows lymphatic c
and partly distended (arrowheads) in Aspp1−/− embryos. (K, L) At E15.5, collecting v
embryos. Note that lymphatic islands (arrows) are detected in Aspp1−/− embryos. Scal
performed with an antibody to LYVE-1 at E17.5. (M, N) Lymphatics extended from th
(arrowheads) in Aspp1−/− embryos. Scale bars, 200 μm. (O, P) Lymphatic vessel netw
hearts. Scale bars, 500 μm. (Q) Number of lymphatic islands on the surface of heartSubcutaneous edema was also seen in Aspp1−/− embryos at
mid-gestation (Fig. 3B, arrowheads). Sections stained with
hematoxylin and eosin showed a thicker dermal layer and more
distended lymphatic vessels in the skin of Aspp1−/− embryosdouble fluorescence confocal microscopy of embryonic back skin was performed
L). (A, B, G, H) Blood vessels visualized by PECAM-1 staining appear relatively
apillary network in Aspp1+/− embryos, whereas lymphatic vessels are disorganized
essels are tortuous and distended in Aspp1−/− embryos compared with Aspp1+/−
e bars, 200 μm. (M–P) Whole-mount immunohistochemistry of gut or heart was
e mesentery toward the intestine are affected and lymphatic vessels are distended
ork is disorganized and more lymphatic islands (arrows) are detected in Aspp1−/−
at E17.5. Aspp1+/+, n=3; Aspp1−/−, n=3; ***, pb0.001.
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arrows). The heart was morphologically normal in Aspp1−/−
embryos. To distinguish arteries, veins, and lymphatic vessels,
we performed double fluorescence confocal microscopy of
E14.5 adjacent sections with antibodies to LYVE-1 or α-smooth
muscle actin combined with PECAM-1 antibodies (Figs. 3E,
H). PECAM-1 marks all endothelial cells, whereas localization
of LYVE-1 and α-smooth muscle actin marks lymphatic vessels
and arteries, respectively. Distended lymphatic vessels are de-
tected in Aspp1−/− embryos, whereas blood vessels appear
relatively unaffected (Figs. 3E–H). Measurement of vessel
profiles present that vessel density of lymphatic vessels are
reduced but average size and total area of lymphatic vessels are
elevated in Aspp1−/− embryos (Figs. 3I–K).
Aspp1−/− embryos showed disorganized lymphatic vessels
To investigate network formation of blood vessels and lym-
phatic vessels, we performed whole-mount double fluorescence
confocal microscopy of embryonic back skin using antibodies to
PECAM-1 and LYVE-1 at different developmental time-points.
At E14.5, the PECAM-1+/LYVE-1+ lymphatic capillary network
was detected in Aspp1+/− embryos, whereas lymphatic vessels
were disorganized and partly distended in Aspp1−/− embryos
(Figs. 4A–F, arrowheads). At E15.5, collecting vessels were
tortuous and distended in Aspp1−/− embryos compared with
Aspp1+/− embryos (Figs. 4G–L). Interestingly, isolated ball-like
structures comprised of numerous lymphatic endothelial cells
(which we designate lymphatic islands) were frequently detected
in Aspp1−/− embryos (Figs. 4J, L, arrows). We confirmed that
these lymphatic islands are not connected to other lymphatic
structures by analyzing serial optical sections with confocal
microscopy (data not shown). PECAM-1-single positive bloodFig. 5. Lymphatic function is affected in Aspp1−/− embryos but not in Aspp1−/− adul
forelimbs at E17.5 visualizes a collecting lymphatic vessel in wild-type mice (A). Site
Aspp1−/− embryos, uptake of FITC-dextran is delayed (B), or FITC-dextran flows fr
longer periods of time (C, D), suggesting an vessel obstruction (arrowheads). (E–J)
hindlimb footpad reveals two collecting lymphatic vessels along the ischiatic vein in
dye, indicating that they are functional. However, Aspp1−/−mice exhibit abnormal lym
vein (F, G), tortuous (G–I), distended (J), or fused to form a single vessel (I). Scalevessels were relatively unaffected in Aspp1−/− embryos. At
E16.5, a defective lymphatic network and lymphatic islands were
still detected in Aspp1−/− embryos (Fig. S1, arrows).
We also checked lymphatic vessels in other internal organs
such as gut and heart by whole-mount immunohistochemistry
with LYVE-1 antibody. A recent study suggested that lymphatics
in the gut are derived from mesenteric lymphatics through an
active branching process supported by a set of LYVE-1+
macrophages during mouse embryonic development (Kim et
al., 2007). Our analysis also detected many singular LYVE-1+
cells which could be macrophages in the mesentery and gut wall
of both wild-type and Aspp1−/− embryos. Lymphatic endothelial
cells were extended from the mesentery toward the intestine in
wild-type embryos, but this extension was impaired and lympha-
tic vessels were distended in the mesentery of Aspp1−/− embryos
(Figs. 4M, N, arrowheads). On the surface of heart, lymphatic
vessel network was disorganized in Aspp1−/− embryos (Fig. 4P).
Similar to Aspp1−/− embryonic skin, more lymphatic islands
were detected in Aspp1−/− heart compared to controls (Fig. 4P,
arrows; Fig. 4Q). These results indicate that Aspp1 is required for
normal development of a primary lymphatic network.
Lymphatic drainage function was impaired in Aspp1−/−
embryos
To determine whether structural defects seen in lymphatic
vessels lead to impaired lymphatic drainage, we assessed
lymphatic function by injecting high-molecular-weight FITC-
dextran into embryonic limbs. Lymphangiography showed
normal collecting lymphatic vessels in wild-type mice at E17.5
(Fig. 5A). However, dye uptake was delayed in Aspp1−/−
embryos, and dye flowed from collecting vessels into branches of
the disorganized lymphatic network about 10 min after dyet mice. (A–D) Lymphangiography by injection of FITC-dextran into embryonic
s of injection are indicated by dashed circles. Time after injection is indicated. In
om collecting vessels into branches of the disorganized lymphatic network after
Lymphangiography by injection of Evans blue dye into the adult (6-week-old)
wild-type mice (E). In Aspp1−/− adult mice, lymphatic vessels carry Evans blue
phatic patterns; collecting lymphatic vessels are missing on one side of ischiatic
bars, 500 μm.
156 M. Hirashima et al. / Developmental Biology 316 (2008) 149–159injection, suggesting vessel obstruction (Figs. 5B–D) and
functional defects in lymphatic drainage of Aspp1−/− embryos.
Interestingly, despite embryonic subcutaneous edema, we did not
detect signs of edema in Aspp1−/− adult mice. Consistent with
this phenotype, lymphangiography by injection of Evans blue
dye into the footpad of adult mice showed functional lymphatic
vessels carrying dye in both wild-type and Aspp1−/− mice (Figs.
5E–J). We also detected normal valves preventing backflow of
the lymph in both wild-type and Aspp1−/− mice (data not shown).
In wild-type mice, two collecting lymphatic vessels were
visualized along the ischiatic vein (Fig. 5E). However, collecting
lymphatic vessels along both sides of the ischiatic vein were
missing and appeared tortuous, distended, or fused to form single
vessels in Aspp1−/− mice (Figs. 5F–J). These results indicate that
lymphatics in Aspp1−/− adult mice are phenotypically abnormally
but sufficient in drainage function.Fig. 6. Lymphatic endothelial cell differentiation and proliferation are normal but c
confocal microscopy was performed with antibodies to PECAM-1 (red) and Prox1 (g
were detected as PECAM-1+/Prox1+ cells. da, dorsal aorta. Scale bars, 100 μm. (C) Fl
1, LYVE-1, and CD45 at E11.5. CD45− population is shown. (D) Determination of
incorporation in Prox1+ skin lymphatic endothelial cells at E14.5. (F) Determinati
endothelial cells in the skin at E14.5. (G) Expression of Prox1 transcripts was determi
purified from skin at E14.5. (H, I) Fluorescence confocal microscopy of embryonic b
lymphatic endothelial cells are present in Aspp1−/− embryos (I). Scale bars, 50 μm. (J
skin was performed with antibodies to VE-cadherin (red) and Podoplanin (green) at E
(arrowheads) of lymphatic endothelial cells in wild-type and Aspp1−/− embryos. ScaLymphatic endothelial cell morphology is abnormal in
Aspp1−/− embryos
We next examined cellular mechanisms underlying lympha-
tic phenotypes in Aspp1−/− embryos. To investigate lymphatic
endothelial cell differentiation, we performed double fluores-
cence confocal microscopy with antibodies to PECAM-1 and
Prox1 at E11.5. A restricted subpopulation of endothelial cells
in the cardinal vein expresses Prox1 and starts migrating toward
the dorsolateral side of embryos where VEGF-C is expressed
(Karkkainen et al., 2004; Wigle and Oliver, 1999). We detected
a PECAM-1+/Prox1+ lymphatic endothelial cell population at
the dorsolateral part of the cardinal vein in both wild-type and
Aspp1−/− embryos at E11.5 (Figs. 6A, B). Flowcytometric
analysis showed that the number of PECAM-1+/LYVE-1+/
CD45− lymphatic endothelial cells was comparable betweenell morphology is abnormal in Aspp1−/− embryos. (A, B) Double fluorescence
reen) at E11.5. Lymphatic endothelial cells budding from the cardinal vein (cv)
owcytometry of dissociated embryos was performed with antibodies to PECAM-
the number of Prox1+ nuclei in the skin at E14.5. (E) Determination of BrdU
on of the proportion of Ki67+/Podoplanin+ proliferating cells to all lymphatic
ned by quantitative real-time PCR analysis in PECAM-1+/LYVE-1+/CD45− cells
ack skin was performed with antibodies to Podoplanin at E14.5. Note that spiky
–O) Whole-mount double fluorescence confocal microscopy of embryonic back
14.5. VE-cadherin is localized at cell–cell junction (arrows) but not protrusions
le bars, 50 μm.
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that the initial differentiation into lymphatic endothelial cells is
normal in Aspp1−/− embryos. As morphological abnormalities
of the lymphatic network were detected at E14.5, we asked if
defects in lymphatic network formation were caused by a
change in the number of lymphatic endothelial cells. To address
this question, we performed fluorescence confocal microscopy
of embryonic back skin with antibodies to Prox1 and measured
the number of Prox1+ nuclei. This analysis showed that the
number of lymphatic endothelial cells was also normal in
Aspp1−/− embryos at E14.5 (Fig. 6D). Immunohistochemical
analysis of incorporated BrdU and a proliferation marker Ki67,
and an apoptosis marker of cleaved caspase-3 did not detect
differences between littermate control and Aspp1−/− embryos at
E14.5 (Figs. 6E, F; data not shown). These results indicate the
defective lymphatic morphogenesis did not result from a change
in the number and proliferation activity of lymphatic endothelial
cells. Since it is reported that Prox1 haploinsufficiency results in
mispatterned lymphatic vasculature (Harvey et al., 2005), we
measured levels of Prox1 transcripts in embryos. To do so, we
sorted PECAM-1+/LYVE-1+/CD45− lymphatic endothelial
cells from embryonic back skin at E14.5 and performed
quantitative real-time PCR analysis for Prox1; however, Prox1
expression levels were not affected (Fig. 6G). Podoplanin is a
mucin-type transmembrane glycoprotein, and is predominantly
expressed in lymphatic endothelial cells (Kriehuber et al., 2001;
Schacht et al., 2003) where it colocalizes in filopodia-like
structures with ERM proteins (Wicki et al., 2006). Immunohis-
tochemical analysis of Podoplanin revealed a morphological
difference between wild-type and Aspp1−/− embryos at E14.5;
single spiky lymphatic endothelial cells were seen in Aspp1−/−
embryos (Fig. 6I). Although lymphatic endothelial cells also
exhibited protruding filopodia in wild-type embryos, we never
detected isolated cells in wild-type embryos. Taken together,
these results indicate that Aspp1 regulates morphology of
lymphatic endothelial cells. To address whether VE-cadherin
mediates lymphatic endothelial cell–cell adhesion in Aspp1−/−
embryos, we performed whole-mount double fluorescence
confocal microscopy of embryonic back skin using antibodies
to VE-cadherin and Podoplanin at E14.5. This analysis showedFig. 7. Loss of p53 does not affect lymphatic vessel development. (A–I) Lymphang
footpad reveals two collecting lymphatic vessels along the ischiatic vein in wild-typ
p53+/− (D), p53+/−; Aspp1+/− (E), p53−/− (G), and p53−/−; Aspp1+/− (H) mice. Abnor
dosage (C), Aspp1−/−; (F), p53+/−; Aspp1−/−; (I), p53−/−; Aspp1−/− mice. Scale bars,that VE-cadherin is localized at cell–cell junction but not
protrusions of lymphatic endothelial cells both in wild-type and
Aspp1−/− embryos (Figs. 6J–O, arrows and arrowheads).
Lymphatic phenotype of Aspp1 mutant mice was not affected by
p53 deficiency or haploinsufficiency
It is reported that Aspp1 enhances apoptotic activity of p53
and that the function of a family member Aspp2 overlaps with
p53 in mouse development. To investigate whether Aspp1
functions with p53 in lymphatic vessel development, we crossed
Aspp1 mutants with p53 knockout mice and performed lym-
phangiography by injecting Evans blue dye into the footpad of
adult mice obtained from Aspp1+/−; p53+/− intercrosses (Figs.
7A–I). p53 deficiency did not result in abnormal lymphatic
development in Aspp1 wild-type or heterozygotes (Figs. 7G, H).
However, homozygous Aspp1 mutant mice showed abnormal
lymphatic development (Figs. 7C, F, I). These lymphatic
phenotypes were not enhanced or suppressed by decreases in
p53 gene dosage. These results indicate that Aspp1 plays a role
in lymphatic vessel development in a p53-independent manner.
Discussion
Consistent with our previous result in a gene-trapped mouse
line (Hirashima et al., 2004), Aspp1 expression was detected in
embryonic blood vessels. On the other hand, its expression in
lymphatic endothelial cells was observed for the first time. It is
noteworthy that the formation of lymphatic vessels rather than
blood vessels was affected in Aspp1−/− mice. Previous reports
showed that only lymphatic vessel formation was impaired
following mutations in genes expressed in both blood vessels
and lymphatic endothelial cells. ephrinB2 is critical to establish
a hierarchical structure of blood vessels (Adams et al., 1999;
Wang et al., 1998); however, mice carrying a mutant ephrinB2
with deletion of the PDZ interaction site showed defective
lymphatic vessels without impaired blood vessel formation
(Makinen et al., 2005). Neuropilin-2 is first detected in venous
endothelial cells and eventually confined to lymphatics, but
only lymphatic vessel development was affected in Neuropilin-iography by injection of Evans blue dye into the adult (6-week-old) hindlimb
e mice (A). Lymphatic patterns of collecting lymphatic vessels were normal in
mal lymphatic patterns seen in Aspp1−/− mice were not influenced by p53 gene
500 μm.
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cellular mechanisms of lymphatic vessel development may
differ slightly from those of blood vessel development.
It has been shown that an initial lymphatic capillary plexus in
the skin remodels into a hierarchical vessel network comprised
of collecting lymphatic vessels and lymphatic capillaries in
early postnatal life (Makinen et al., 2005). Aspp1−/− mice
showed a disorganized lymphatic plexus and impaired lympha-
tic drainage function in embryonic skin, whereas the lymphatic
drainage defect was resolved in adults. Thus lymphatic
endothelial cells likely require a longer time but can eventually
form a functional network in the absence of Aspp1. Moreover,
collecting lymphatic vessels of Aspp1−/− adult mice possess
luminal valves. These results indicate that Aspp1 is important
for the initial assembly of lymphatic endothelial cells but
dispensable for lymphatic remodeling. Interestingly, isolated
lymphatic islands were frequently detected in the skin and heart
of Aspp1−/− embryos. These lymphatic islands were also de-
tected in wild-type embryos (Fig. S2), although less frequently
than in Aspp1−/− embryos. Lymphatic islands may connect with
one another to form lymphatic vasculature in some tissues, and
these connection processes may be delayed in Aspp1−/−
embryos.
We detected single spiky lymphatic endothelial cells in the
skin of Aspp1−/− embryos. Although lymphatic endothelial
cells also exhibit protruding filopodia in wild-type embryos, we
never detected isolated cells in wild-type embryos. Immuno-
histochemical analysis showed that VE-cadherin is localized
at cell–cell junction of lymphatic endothelial cells both in
Aspp1−/− embryos, indicating that static cell–cell adhesion is
not impaired. However, since VE-cadherin is not localized at
filopodial protrusions even in wild-type lymphatic endothelial
cells, VE-cadherin might not mediate the primary process of
lymphatic endothelial cell–cell adhesion. Thus we cannot
rule out the possibility that cell–cell adhesion is impaired in
Aspp1−/− embryos. These results suggest that Aspp1 regulates
cell–cell adhesion, migration, or cytoskeletal changes rather
than the number of lymphatic endothelial cells. Morphological
changes at the cellular level lead to disorganized lymphatic
vasculature in Aspp1−/− embryos. It is likely that disorganized
primary lymphatic capillary plexus results in mispatterned
collecting lymphatic vessels detected by lymphangiography in
Aspp1−/− adult mice. Alternatively, there might be putative
developmental cues for alignment between blood and lymphatic
vessels that do not function properly in Aspp1−/− mice.
Subcutaneous edema observed in Aspp1−/− embryos is
reminiscent of increased nuchal translucency in human fetuses,
which is widely used to determine the risk of chromosomal
abnormalities (Haak and van Vugt, 2003). Since increased
nuchal translucency also occurs in fetuses with normal karyo-
types, mutations in the Aspp1 gene may cause this condition.
Lymphatic drainage improved as development of Aspp1−/−
mice proceeded, and vascular permeability was not increased in
Aspp1−/− adult mice (data not shown). Although Aspp1−/− pups
were growth-retarded, Aspp1−/− mice lived for more than 1 year
without overt abnormality. Most pups with mutations giving
rise to defective lymphatic vessels die within weeks after birth,owing to respiratory distress caused by chylothorax and/or
chylous ascites. For instance, Angiopoietin-2-deficient mice
have disorganized lymphatic vessels with poor smooth muscle
cell coverage and develop chylous ascites (Gale et al., 2002).
Targeted mutation in the Net gene results in chylothorax with
distended lymphatic vessels of the thoracic wall (Ayadi et al.,
2001). Mice deficient in integrin α9 also develop chylothorax
with a defective thoracic duct (Huang et al., 2000). A
correlation between accumulation of chylous fluid and postnatal
lethality was also observed following analysis of Chy mice
(Karkkainen et al., 2001). On the other hand, Aspp1−/− embryos
showed functional defects in subcutaneous lymphatic vessels at
late gestation but did not develop abnormal fluid accumulation
in the thoracic or abdominal cavity (data not shown). This
probably accounts for Aspp1−/− mouse survival despite lym-
phatic functional defects during embryogenesis.
It has been reported that Aspp1 enhances apoptotic activity
of the tumor-suppressor p53 and that Aspp2 function in mouse
development overlaps with that of p53. The lymphatic pheno-
type of Aspp1 mutant mice, however, was not affected by p53
deficiency or haploinsufficiency, indicating that Aspp1 func-
tions during lymphatic vessel development in a p53-indepen-
dent manner. Molecular mechanisms underlying the role of
Aspp1 in lymphatic endothelial cells remain to be elucidated,
but our study clearly presents a novel role of this endothelial-
specific p53-binding protein in the initial assembly and function
of lymphatic vessels during mouse embryogenesis.
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